Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination
Chukiat Sirivichayakul,Shibadas Biswal,Xavier Saez-Llorens,Eduardo López-Medina,Charissa Borja-Tabora,Lulu Bravo,Pope Kosalaraksa,Maria Theresa Alera,Humberto Reynales,Luis Rivera,Veerachai Watanaveeradej,Delia Yu,Felix Espinoza,Reynaldo Dietze,LakKumar Fernando,V Pujitha Wickramasinghe,Edson Duarte Moreira,Asvini D Fernando,Dulanie Gunasekera,Kleber Luz,Rivaldo Venâncio da Cunha,Ana Lucia Oliveira,Martina Rauscher,Huihao Fan,Astrid Borkowski,Ian Escudero,Suely Tuboi,Eric Lloyd,Vianney Tricou,Nicolas Folschweiller,Inge LeFevre,Luis Martinez Vargas,Derek Wallace,Asvini Fernando,Charissa Borja-Tabora,Chukiat Sirivichayakul,Delia Yu,Dulanie Gunasekera,Eduardo López-Medina,Edith Johanna Rodriguez-Arenales,Edson Duarte Moreira,Felix Espinoza,Hector Velásquez,Humberto Reynales,Kleber Luz,Jose Jimeno,Rodrigo deAntonio,Elaine Aranguren,LakKumar Fernando,Lulu Bravo,Luis Martinez Vargas,Luis Rivera,Maria Theresa Alera,Onanong Manacharoen,Pio Lopez,Pope Kosalaraksa,V Pujitha Wickramasinghe,Reynaldo Dietze,Rivaldo Venâncio da Cunha,Veerachai Watanaveeradej,Xavier Saez-Llorens,Shibadas Biswal,Manja Brose,Martina Rauscher,Olaf Zent,Mengya Liu,Elaine Hoffman,Inge LeFevre,Astrid Borkowski,Derek Wallace,Ian Escudero,Ivo Sonderegger,Yanee Hutagalung,Suely Tuboi,Vianney Tricou,for the TIDES Study Group
DOI: https://doi.org/10.1093/infdis/jiae222
2024-04-30
The Journal of Infectious Diseases
Abstract:We explored the impact of prior Yellow fever (YF) or Japanese encephalitis (JE) vaccination on the efficacy of Takeda's dengue vaccine candidate, TAK-003 ( NCT02747927 ). Children 4–16 years of age were randomized 2:1 to receive TAK-003 or placebo and were under active febrile surveillance. Symptomatic dengue was confirmed by serotype-specific RT-PCR. YF and JE vaccination history was recorded. Of the 20,071 children who received TAK-003 or placebo, 21.1% had a YF and 23.9% had a JE vaccination history at randomization. Fifty-seven months after vaccination, vaccine efficacy was 55.7% (95% CI, 39.7%-67.5%) in those with YF vaccination, 77.8% (70.8%-83.1%) for JE vaccination, and 53.5% (45.4%-60.4%) for no prior YF/JE vaccination. Regional differences in serotype distribution confound these results. The apparent higher vaccine efficacy in the JE vaccination subgroup could be largely explained by serotype-specific efficacy of TAK-003. Within 28 days of any vaccination, the proportions of participants with serious adverse events in the YF/JE prior vaccination population were comparable between the TAK-003 and placebo groups. The available data do not suggest a clinically relevant impact of prior JE or YF vaccination on TAK-003 performance. Overall, TAK-003 was well-tolerated and efficacious in different epidemiological settings.
immunology,infectious diseases,microbiology